Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May;23(5):516-517.
doi: 10.1634/theoncologist.2017-0644. Epub 2018 Feb 14.

Panobinostat and Multiple Myeloma in 2018

Andrew J Yee  1   2 , Noopur S Raje  3   2
Affiliations

Panobinostat and Multiple Myeloma in 2018

Andrew J Yee et al. Oncologist. 2018 May.

Abstract

FDA and EMA approval of panobinostat offers an additional therapeutic option for multiple myeloma; however, adoption of panobinostat has been limited by its adverse event profile. Trials are ongoing to optimize the dosing of panobinostat and to identify its best partners, in order to fully realize the potential of this drug class.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

References

    1. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38–51. - PubMed
    1. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004;10:3839–3852. - PubMed
    1. Richardson PG, Mitsiades CS, Laubach JP et al. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res 2013;37:829–837. - PubMed
    1. Moreau P, Richardson PG, Cavo M et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012;120:947–959. - PMC - PubMed
    1. Dimopoulos M, Siegel DS, Lonial S et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): A multicentre, randomised, double‐blind study. Lancet Oncol 2013;14:1129–1140. - PubMed

Publication types